Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Administrations of MWN105 Injection in Chinese Non-Diabetic Participants With Overweight or Obesity
NCT07803809 is registered in ClinicalTrials.gov with Shanghai Minwei Biotechnology Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Administrations of MWN105 Injection in Chinese Non-Diabetic Participants With Overweight or Obesity
- Lead sponsor
- Shanghai Minwei Biotechnology Co., Ltd
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- April 26, 2026
- Completion date
- January 31, 2027
- Enrollment
- 36 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
mash - metabolic dysfunction-associated steatohepatitis, overweight , obesity, type 2 diabetes mellitus (t2dm)